

Bryce A Kerlin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3236680/publications.pdf>

Version: 2024-02-01

86
papers

2,389
citations

257450

24
h-index

214800

47
g-index

91
all docs

91
docs citations

91
times ranked

2630
citing authors

#	ARTICLE	IF	CITATIONS
1	Epidemiology and Pathophysiology of Nephrotic Syndrome-associated Thromboembolic Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2012, 7, 513-520.	4.5	256
2	Survival advantage associated with heterozygous factor V Leiden mutation in patients with severe sepsis and in mouse endotoxemia. <i>Blood</i> , 2003, 102, 3085-3092.	1.4	209
3	An Orthogonal Array Optimization of Lipid-like Nanoparticles for mRNA Delivery in Vivo. <i>Nano Letters</i> , 2015, 15, 8099-8107.	9.1	182
4	Pediatric venous thromboembolism in the United States: A tertiary care complication of chronic diseases. <i>Pediatric Blood and Cancer</i> , 2012, 59, 258-264.	1.5	155
5	Characterization of a Mouse Model for Thrombomodulin Deficiency. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2001, 21, 1531-1537.	2.4	138
6	Epidemiology and Risk Factors for Thromboembolic Complications of Childhood Nephrotic Syndrome: A Midwest Pediatric Nephrology Consortium (MWPNC) Study. <i>Journal of Pediatrics</i> , 2009, 155, 105-110.e1.	1.8	120
7	Crucial role for the VWF A1 domain in binding to type IV collagen. <i>Blood</i> , 2015, 125, 2297-2304.	1.4	88
8	AKI in Children Hospitalized with Nephrotic Syndrome. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 2110-2118.	4.5	87
9	The emerging role of coagulation proteases in kidney disease. <i>Nature Reviews Nephrology</i> , 2016, 12, 94-109.	9.6	81
10	Cause-effect relation between hyperfibrinogenemia and vascular disease. <i>Blood</i> , 2004, 103, 1728-1734.	1.4	80
11	The Cost of Pediatric Stroke Care and Rehabilitation. <i>Stroke</i> , 2008, 39, 161-165.	2.0	76
12	Venous thromboembolism in pediatric nephrotic syndrome. <i>Pediatric Nephrology</i> , 2014, 29, 989-997.	1.7	69
13	Current and future management of pediatric venous thromboembolism. <i>American Journal of Hematology</i> , 2012, 87, S68-74.	4.1	47
14	Desmopressin responsiveness in children with Ehlers-Danlos syndrome associated bleeding symptoms. <i>British Journal of Haematology</i> , 2009, 144, 230-233.	2.5	44
15	Congenital amegakaryocytic thrombocytopenia: The diagnostic importance of combining pathology with molecular genetics. <i>Pediatric Blood and Cancer</i> , 2008, 50, 1263-1265.	1.5	37
16	Increasing frequency of acute kidney injury amongst children hospitalized with nephrotic syndrome. <i>Pediatric Nephrology</i> , 2014, 29, 139-147.	1.7	37
17	Role of direct oral anticoagulants in patients with kidney disease. <i>Kidney International</i> , 2020, 97, 664-675.	5.2	35
18	Thrombin-Induced Podocyte Injury Is Protease-Activated Receptor Dependent. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 2618-2630.	6.1	34

#	ARTICLE	IF	CITATIONS
19	Factor V Leiden polymorphism modifies sepsis outcome: Evidence from animal studies. <i>Critical Care Medicine</i> , 2004, 32, S233-S238.	0.9	33
20	Bleeding symptoms and laboratory correlation in patients with severe von Willebrand disease. <i>Haemophilia</i> , 2009, 15, 918-925.	2.1	30
21	BAY 81-8973 safety and efficacy for prophylaxis and treatment of bleeds in previously treated children with severe haemophilia A: results of the LEOPOLD Kids Trial. <i>Haemophilia</i> , 2016, 22, 354-360.	2.1	29
22	Association of infections and venous thromboembolism in hospitalized children with nephrotic syndrome. <i>Pediatric Nephrology</i> , 2019, 34, 261-267.	1.7	29
23	Protease-activated receptors: An illustrated review. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, 17-26.	2.3	27
24	The PFA-100 does not predict delta-granule platelet storage pool deficiencies. <i>Haemophilia</i> , 2012, 18, 626-629.	2.1	26
25	Disease Severity Correlates with Thrombotic Capacity in Experimental Nephrotic Syndrome. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 3009-3019.	6.1	23
26	Development of a pediatric-specific clinical probability tool for diagnosis of venous thromboembolism: a feasibility study. <i>Pediatric Research</i> , 2015, 77, 463-471.	2.3	22
27	Recombinant FXIII (rFXIII-A2) Prophylaxis Prevents Bleeding and Allows for Surgery in Patients with Congenital FXIII A-Subunit Deficiency. <i>Thrombosis and Haemostasis</i> , 2018, 118, 451-460.	3.4	22
28	Thrombotic Risk of Recombinant Factor Seven in Pediatric Cardiac Surgery: A Single Institution Experience. <i>Annals of Thoracic Surgery</i> , 2010, 89, 570-576.	1.3	21
29	Pharmacokinetics of recombinant factor XIII at steady state in patients with congenital factor XIII A-subunit deficiency. <i>Journal of Thrombosis and Haemostasis</i> , 2014, 12, 2038-2043.	3.8	21
30	State of the art in factor XIII laboratory assessment. <i>Transfusion and Apheresis Science</i> , 2018, 57, 700-704.	1.0	21
31	Variability in bleeding phenotype in Amish carriers of haemophilia B with the 31008 C>T mutation. <i>Haemophilia</i> , 2009, 15, 91-100.	2.1	19
32	Healthcare burden of venous thromboembolism in childhood chronic renal diseases. <i>Pediatric Nephrology</i> , 2015, 30, 829-837.	1.7	19
33	Concurrent poststreptococcal glomerulonephritis and autoimmune hemolytic anemia. <i>Pediatric Nephrology</i> , 2003, 18, 1301-1303.	1.7	16
34	Reference Range of Platelet Delta Granules in the Pediatric Age Group: An Ultrastructural Study of Platelet Whole Mount Preparations from Healthy Volunteers. <i>Pediatric and Developmental Pathology</i> , 2016, 19, 498-501.	1.0	16
35	Developing the First Recombinant Factor XIII for Congenital Factor XIII Deficiency: Clinical Challenges and Successes. <i>Seminars in Thrombosis and Hemostasis</i> , 2017, 43, 059-068.	2.7	15
36	Social and Ethical Controversies in Thrombophilia Testing and Update on Genetic Risk Factors for Venous Thromboembolism. <i>Seminars in Thrombosis and Hemostasis</i> , 2008, 34, 549-561.	2.7	14

#	ARTICLE	IF	CITATIONS
37	Thrombosis of the Abdominal Veins in Childhood. <i>Frontiers in Pediatrics</i> , 2017, 5, 188.	1.9	14
38	Applying diagnostic criteria for type 1 von Willebrand disease to a pediatric population. <i>Pediatric Blood and Cancer</i> , 2009, 52, 102-107.	1.5	13
39	Pharmacokinetic characterization of recombinant factor XIII (FXIII)â€A2 across age groups in patients with FXIII Aâ€subunit congenital deficiency. <i>Haemophilia</i> , 2015, 21, 380-385.	2.1	13
40	Nephrotic syndrome disease activity is proportional to its associated hypercoagulopathy. <i>Thrombosis Research</i> , 2021, 201, 50-59.	1.7	13
41	Epidemiology of bleeding symptoms and hypermobile Ehlersâ€Danlos syndrome in paediatrics. <i>Haemophilia</i> , 2016, 22, e490-3.	2.1	12
42	Light Transmission Aggregometry Does Not Correlate With the Severity of Î-Granule Platelet Storage Pool Deficiency. <i>Journal of Pediatric Hematology/Oncology</i> , 2016, 38, 525-528.	0.6	12
43	Treatment-Related Outcomes in Pagetâ€Schroetter Syndromeâ€A Cross-Sectional Investigation. <i>Journal of Pediatrics</i> , 2019, 207, 226-232.e1.	1.8	12
44	Validation Study of the Composite Score to Identify Von Willebrand Disease in Children. <i>Journal of Pediatric Hematology/Oncology</i> , 2016, 38, 139-142.	0.6	11
45	Low bleeding rates with increase or maintenance of physical activity in patients treated with recombinant factor <sc>VIII</sc> Fc fusion protein (<sc>rFVIII</sc>c) in the Aâ€LONG and Kids Aâ€<sc>LONG</sc> Studies. <i>Haemophilia</i> , 2017, 23, e39-e42.	2.1	10
46	Temozolomide and Radiation for Aggressive Pediatric Central Nervous System Malignancies. <i>Journal of Pediatric Hematology/Oncology</i> , 2005, 27, 254-258.	0.6	9
47	Prevalence of abnormal bone density of pediatric patients prior to blood or marrow transplant. <i>Pediatric Blood and Cancer</i> , 2009, 53, 675-677.	1.5	9
48	Recombinant factorâXIII prophylaxis is safe and effective in young children with congenital factor XIIIâ€A deficiency: international phaseâ3b trial results. <i>Journal of Thrombosis and Haemostasis</i> , 2017, 15, 1601-1606.	3.8	9
49	Recommendations for Screening for Thrombophilic Tendencies in Teenage Females Prior to Contraceptive Initiation. <i>Journal of Pediatric and Adolescent Gynecology</i> , 2006, 19, 313-316.	0.7	8
50	Fibrinogen Columbus: a novel gamma Gly200Val mutation causing hypofibrinogenemia in a family with associated thrombophilia. <i>Haematologica</i> , 2007, 92, 1151-1152.	3.5	7
51	Nephrotic syndromeâ€associated hypercoagulopathy is alleviated by both pioglitazone and glucocorticoid which target two different nuclear receptors. <i>Physiological Reports</i> , 2020, 8, e14515.	1.7	7
52	Plasma Cytokine Profiling to Predict Steroid Resistance in Pediatric Nephrotic Syndrome. <i>Kidney International Reports</i> , 2021, 6, 785-795.	0.8	7
53	A Review of Hormonal Contraception and Venous Thromboembolism in Adolescents. <i>Journal of Pediatric and Adolescent Gynecology</i> , 2016, 29, 402-408.	0.7	6
54	A pilot randomized trial of atorvastatin as adjunct therapy in patients with acute venous thromboembolism. <i>Blood Coagulation and Fibrinolysis</i> , 2021, 32, 16-22.	1.0	5

#	ARTICLE	IF	CITATIONS
55	Thrombolysis for pediatric venous thromboembolism: Is it time for a trial?. <i>Pediatric Blood and Cancer</i> , 2009, 53, 920-921.	1.5	4
56	Activated Partial Thromboplastin Time versus Anti-Factor Xa Levels for Monitoring Unfractionated Heparin Therapy in Children: An Institutional Experience. <i>Journal of Pediatric Hematology/Oncology</i> , 2017, 39, 576-577.	0.6	4
57	Use of electronic self-administered bleeding assessment tool in diagnosis of paediatric bleeding disorders. <i>Haemophilia</i> , 2021, 27, 710-716.	2.1	3
58	Safety and effectiveness of recombinant factor XIII ^{A2} in congenital factor XIII deficiency: Real-world evidence. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, e12628.	2.3	3
59	Selective modulator of nuclear receptor PPAR ^γ 3 with reduced adipogenic potential ameliorates experimental nephrotic syndrome. <i>IScience</i> , 2022, 25, 104001.	4.1	3
60	Venous thromboembolism in chronic pediatric heart disease is associated with substantial health care burden and expenditures. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2019, 3, 372-382.	2.3	2
61	Inpatient Health Care Utilization in Children With Hemophilia Before and After the Joint Outcome Study Publication. <i>Journal of Pediatric Hematology/Oncology</i> , 2019, 41, e284-e289.	0.6	2
62	Drive-Through Anticoagulation Clinic During the COVID-19 Pandemic. <i>Journal for Nurse Practitioners</i> , 2022, 18, 92-96.	0.8	2
63	Low Bleeding Rates with Increase or Maintenance of Physical Activity in Patients Treated with Recombinant Factor VIII Fc Fusion Protein (rFVIII ^{Fc}) in the A-LONG and Kids A-LONG Studies. <i>Blood</i> , 2015, 126, 3543-3543.	1.4	2
64	Long-Term Efficacy and Quality of Life with Recombinant Factor VIII Fc Fusion Protein (rFVIII ^{Fc}) Prophylaxis in Pediatric, Adolescent, and Adult Subjects with Target Joints and Severe Hemophilia a. <i>Blood</i> , 2016, 128, 3791-3791.	1.4	2
65	An Update on rFVIIa Use in Females with Rare Bleeding Disorders. <i>Blood</i> , 2019, 134, 1119-1119.	1.4	2
66	Moderate-intensity aerobic exercise vs desmopressin in adolescent males with mild hemophilia A: a randomized trial. <i>Blood</i> , 2022, 140, 1156-1166.	1.4	2
67	Variation in Platelet Delta Granules Over Time in Young Women Undergoing Evaluation for Heavy Menstrual Bleeding. <i>Pediatric and Developmental Pathology</i> , 2019, 22, 123-127.	1.0	1
68	Nephrotic Syndrome Clots Are Resistant to Fibrinolysis Despite Elevated Plasmin Generation. <i>Blood</i> , 2016, 128, 3767-3767.	1.4	1
69	Endogenous Thrombin Potential is Directly Correlated with Proteinuria Severity in Both Nephrotic Syndrome Patients and an Animal Model of Nephrotic Syndrome. <i>Blood</i> , 2014, 124, 4243-4243.	1.4	1
70	Hemolytic Anemia in a 5-Year-Old Child. <i>Laboratory Medicine</i> , 2006, 37, 746-748.	1.2	0
71	Common clinical variables predict warfarin maintenance dose and therapeutic resistance. <i>Journal of Thrombosis and Thrombolysis</i> , 2008, 25, 101-101.	2.1	0
72	Pulmonary morbidity of catheter-related pediatric venous thromboembolism: Old problem, new worry*. <i>Critical Care Medicine</i> , 2011, 39, 1234-1235.	0.9	0

#	ARTICLE	IF	CITATIONS
73	Bleeding Associated with Connective Tissue Disorders. , 2021, , 201-209.		0
74	Pediatric Venous Thromboembolism: Redefining Epidemiology.. Blood, 2009, 114, 5055-5055.	1.4	0
75	The PFA-100 Does Not Predict Delta-Granule Platelet Storage Pool Deficiencies. Blood, 2010, 116, 2518-2518.	1.4	0
76	Thrombin Generation Is Directly Correlated To Proteinuria Severity In An Experimental Model Of Nephrotic Syndrome. Blood, 2013, 122, 3615-3615.	1.4	0
77	Pharmacokinetic Characterisation Of Recombinant FXIII Across Age Groups In Patients With FXIII Subunit A Congenital Deficiency. Blood, 2013, 122, 3613-3613.	1.4	0
78	Thrombin Induces Apoptosis in Human and Rat Podocytes in a Protease Activated Receptor (PAR)-Dependent Manner. Blood, 2014, 124, 2808-2808.	1.4	0
79	New Data on the Safety and Efficacy of Recombinant FXIII in Patients with Congenital FXIII A-Subunit Deficiency. Blood, 2014, 124, 1520-1520.	1.4	0
80	Long-Term Efficacy of rFVIII Fc Prophylaxis in Pediatric, Adolescent, and Adult Subjects with Target Joints and Severe Hemophilia A. Blood, 2015, 126, 3520-3520.	1.4	0
81	Infections Are Associated with Higher Risk of Venous Thromboembolism in Hospitalized Children with Nephrotic Syndrome. Blood, 2016, 128, 3811-3811.	1.4	0
82	Safety and Efficacy of Recombinant Factor XIII (FXIII) in Patients with Congenital FXIII A-Subunit Deficiency, Results from the Mentorâ„¢2 Trial. Blood, 2016, 128, 2573-2573.	1.4	0
83	Thrombin Generation in Nephrotic Syndrome Is Dependent on Remission Status and Hypercholesterolemia. Blood, 2019, 134, 2422-2422.	1.4	0
84	Recognition and Care of a Newborn with FXIII Deficiency. , 2020, , 71-80.		0
85	A Novel Assay Using Enzyme Capture - ELISA for Accurate Determination of Factor XIII Activity. Blood, 2020, 136, 23-24.	1.4	0
86	Direct Oral Anticoagulants Reduce Hypercoagulopathy and Preserve Podocyte Function in an Experimental Model of Glomerular Disease. Blood, 2020, 136, 26-26.	1.4	0